TY - JOUR AU - Munn, D. H. AU - Mellor, A. L. PY - 2016 DA - 2016// TI - IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance JO - Trends Immunol VL - 37 UR - https://doi.org/10.1016/j.it.2016.01.002 DO - 10.1016/j.it.2016.01.002 ID - Munn2016 ER - TY - JOUR AU - Uyttenhove, C. AU - Pilotte, L. AU - Théate, I. AU - Stroobant, V. AU - Colau, D. AU - Parmentier, N. PY - 2003 DA - 2003// TI - Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3 dioxygenase JO - Nat Med VL - 9 UR - https://doi.org/10.1038/nm934 DO - 10.1038/nm934 ID - Uyttenhove2003 ER - TY - JOUR AU - Desvignes, L. AU - Ernst, J. D. PY - 2009 DA - 2009// TI - Interferon gamma responsive non hematopoietic cells regulate the immune response to Mycobacterium tuberculosis JO - Immunity VL - 31 UR - https://doi.org/10.1016/j.immuni.2009.10.007 DO - 10.1016/j.immuni.2009.10.007 ID - Desvignes2009 ER - TY - JOUR AU - Favre, D. AU - Mold, J. AU - Hunt, P. W. AU - Kanwar, B. AU - Loke, P. AU - Seu, L. PY - 2010 DA - 2010// TI - Tryptophan catabolism by indoleamine 2,3 dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease JO - Sci Transl Med VL - 2 UR - https://doi.org/10.1126/scitranslmed.3000632 DO - 10.1126/scitranslmed.3000632 ID - Favre2010 ER - TY - JOUR AU - Polak, M. E. AU - Borthwick, N. J. AU - Gabriel, F. G. AU - Johnson, P. AU - Higgins, B. AU - Hurren, J. PY - 2007 DA - 2007// TI - Mechanisms of local immunosuppression in cutaneous melanoma JO - Br J Cancer VL - 96 UR - https://doi.org/10.1038/sj.bjc.6603763 DO - 10.1038/sj.bjc.6603763 ID - Polak2007 ER - TY - JOUR AU - Brody, J. R. AU - Costantino, C. L. AU - Berger, A. C. AU - Sato, T. AU - Lisanti, M. P. AU - Yeo, C. J. PY - 2009 DA - 2009// TI - Expression of indoleamine 2,3 dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival JO - Cell Cycle VL - 8 UR - https://doi.org/10.4161/cc.8.12.8745 DO - 10.4161/cc.8.12.8745 ID - Brody2009 ER - TY - JOUR AU - Witkiewicz, A. AU - Williams, T. K. AU - Cozzitorto, J. AU - Durkan, B. AU - Showalter, S. L. AU - Yeo, C. J. PY - 2008 DA - 2008// TI - Expression of indoleamine 2,3 dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection JO - J Am Coll Surg VL - 206 UR - https://doi.org/10.1016/j.jamcollsurg.2007.12.014 DO - 10.1016/j.jamcollsurg.2007.12.014 ID - Witkiewicz2008 ER - TY - JOUR AU - Okamoto, A. AU - Nikaido, T. AU - Ochiai, K. AU - Takakura, S. AU - Saito, M. AU - Aoki, Y. PY - 2005 DA - 2005// TI - Indoleamine 2,3 dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-2671 DO - 10.1158/1078-0432.CCR-04-2671 ID - Okamoto2005 ER - TY - JOUR AU - Varga, A. AU - Piha-Paul, S. A. AU - Ott, P. A. AU - Mehnert, J. M. AU - Berton-Rigaud, D. AU - Morosky, A. PY - 2017 DA - 2017// TI - Pembrolizumab in patients with PD-L1–positive (PD-L1+) advanced ovarian cancer: updated analysis of KEYNOTE-028 JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.5513 DO - 10.1200/JCO.2017.35.15_suppl.5513 ID - Varga2017 ER - TY - JOUR AU - Curti, A. AU - Pandolfi, S. AU - Valzasina, B. AU - Aluigi, M. AU - Isidori, A. AU - Ferri, E. PY - 2007 DA - 2007// TI - Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25 into CD25+ T regulatory cells JO - Blood VL - 109 ID - Curti2007 ER - TY - JOUR AU - Chamuleau, M. E. AU - van de Loosdrecht, A. A. AU - Hess, C. J. AU - Janssen, J. J. AU - Zevenbergen, A. AU - Delwel, R. PY - 2008 DA - 2008// TI - High INDO (indoleamine 2,3 dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome JO - Haematologica VL - 93 UR - https://doi.org/10.3324/haematol.13112 DO - 10.3324/haematol.13112 ID - Chamuleau2008 ER - TY - JOUR AU - Huang, A. AU - Fuchs, D. AU - Widner, B. AU - Glover, C. AU - Henderson, D. C. AU - Allen-Mersh, T. G. PY - 2002 DA - 2002// TI - Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer JO - Br J Cancer VL - 86 UR - https://doi.org/10.1038/sj.bjc.6600336 DO - 10.1038/sj.bjc.6600336 ID - Huang2002 ER - TY - JOUR AU - Brandacher, G. AU - Perathoner, A. AU - Ladurner, R. AU - Schneeberger, S. AU - Obrist, P. AU - Winkler, C. PY - 2006 DA - 2006// TI - Prognostic value of indoleamine 2,3 dioxygenase expression in colorectal cancer: effect on tumor infiltrating T cells JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-05-1966 DO - 10.1158/1078-0432.CCR-05-1966 ID - Brandacher2006 ER - TY - JOUR AU - Feder-Mengus, C. AU - Wyler, S. AU - Hudolin, T. AU - Ruszat, R. AU - Bubendorf, L. AU - Chiarugi, A. PY - 2008 DA - 2008// TI - High expression of indoleamine 2,3 dioxygenase gene in prostate cancer JO - Eur J Cancer VL - 44 UR - https://doi.org/10.1016/j.ejca.2008.05.023 DO - 10.1016/j.ejca.2008.05.023 ID - Feder-Mengus2008 ER - TY - JOUR AU - Ino, K. AU - Yamamoto, E. AU - Shibata, K. AU - Kajiyama, H. AU - Yoshida, N. AU - Terauchi, M. PY - 2008 DA - 2008// TI - Inverse correlation between tumoral indoleamine 2,3 dioxygenase expression and tumor infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-4144 DO - 10.1158/1078-0432.CCR-07-4144 ID - Ino2008 ER - TY - JOUR AU - Ino, K. AU - Yoshida, N. AU - Kajiyama, H. AU - Shibata, K. AU - Yamamoto, E. AU - Kidokoro, K. PY - 2006 DA - 2006// TI - Indoleamine 2,3 dioxygenase is a novel prognostic indicator for endometrial cancer JO - Br J Cancer VL - 95 UR - https://doi.org/10.1038/sj.bjc.6603477 DO - 10.1038/sj.bjc.6603477 ID - Ino2006 ER - TY - JOUR AU - Beatty, G. L. AU - O'Dwyer, P. J. AU - Clark, J. AU - Shi, J. G. AU - Bowman, K. J. AU - Scherle, P. A. PY - 2017 DA - 2017// TI - First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-2272 DO - 10.1158/1078-0432.CCR-16-2272 ID - Beatty2017 ER - TY - JOUR AU - Gangadhar, T. C. AU - Schneider, B. J. AU - Bauer, T. M. AU - Wasser, J. S. AU - Spira, A. I. AU - Patel, S. P. PY - 2017 DA - 2017// TI - Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: preliminary phase I/II results of ECHO-202/KEYNOTE-037 JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.9014 DO - 10.1200/JCO.2017.35.15_suppl.9014 ID - Gangadhar2017 ER - TY - JOUR AU - Lara, P. AU - Bauer, T. M. AU - Hamid, O. AU - Smith, D. C. AU - Gajewski, T. AU - Gangadhar, T. C. PY - 2017 DA - 2017// TI - Epacadostat plus pembrolizumab in patients with advanced RCC: preliminary phase I/II results from ECHO-202/KEYNOTE-037 JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.4515 DO - 10.1200/JCO.2017.35.15_suppl.4515 ID - Lara2017 ER - TY - JOUR AU - Perez, R. P. AU - Riese, M. J. AU - Lewis, K. D. AU - Saleh, M. N. AU - Daud, A. AU - Berlin, J. PY - 2017 DA - 2017// TI - Epacadostat plus nivolumab in patients with advanced solid tumors: preliminary phase I/II results of ECHO-204 JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.3003 DO - 10.1200/JCO.2017.35.15_suppl.3003 ID - Perez2017 ER - TY - JOUR AU - Smith, D. C. AU - Gajewski, T. AU - Hamid, O. AU - Wasser, J. S. AU - Olszanski, A. J. AU - Patel, S. P. PY - 2017 DA - 2017// TI - Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: preliminary phase I/II results of ECHO-202/KEYNOTE-037 JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.4503 DO - 10.1200/JCO.2017.35.15_suppl.4503 ID - Smith2017 ER - TY - JOUR AU - Mautino, M. R. AU - Link, C. J. AU - Vahanian, N. N. AU - Adams, J. T. AU - Van Allen, C. AU - Sharma, M. D. PY - 2014 DA - 2014// TI - Synergistic antitumor effects of combinatorial immune checkpoint inhibition with anti-PD-1/PD-L antibodies and the IDO pathway inhibitors NLG-919 and indoximod in the context of active immunotherapy JO - Cancer Res VL - 74 ID - Mautino2014 ER - TY - JOUR AU - Li, M. AU - Bolduc, A. R. AU - Hoda, M. N. AU - Gamble, D. N. AU - Dolisca, S. B. AU - Bolduc, A. K. PY - 2014 DA - 2014// TI - The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma JO - J Immunother Cancer VL - 2 UR - https://doi.org/10.1186/2051-1426-2-21 DO - 10.1186/2051-1426-2-21 ID - Li2014 ER - TY - JOUR AU - Berrong, Z. AU - Ahmad, S. AU - Abu Eid, R. AU - El Andaloussi, A. AU - Sen, T. AU - Stewart, R. PY - 2014 DA - 2014// TI - Immune combinational therapy targeting OX40 and IDO synergistically enhances efficacy of a cancer vaccine JO - J Immunother Cancer VL - 2 UR - https://doi.org/10.1186/2051-1426-2-S3-P226 DO - 10.1186/2051-1426-2-S3-P226 ID - Berrong2014 ER - TY - JOUR AU - Spranger, S. AU - Koblish, H. K. AU - Horton, B. AU - Scherle, P. A. AU - Newton, R. AU - Gajewski, T. F. PY - 2014 DA - 2014// TI - Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment JO - J Immunother Cancer VL - 2 UR - https://doi.org/10.1186/2051-1426-2-3 DO - 10.1186/2051-1426-2-3 ID - Spranger2014 ER - TY - JOUR AU - Spira, A. I. AU - Hamid, O. AU - Bauer, T. M. AU - Borges, V. F. AU - Wasser, J. S. AU - Smith, D. C. PY - 2017 DA - 2017// TI - Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: phase I/II ECHO-202 study JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.1103 DO - 10.1200/JCO.2017.35.15_suppl.1103 ID - Spira2017 ER - TY - JOUR AU - Banerjee, T. AU - Duhadaway, J. B. AU - Gaspari, P. AU - Sutanto-Ward, E. AU - Munn, D. H. AU - Mellor, A. L. PY - 2008 DA - 2008// TI - A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase JO - Oncogene VL - 27 UR - https://doi.org/10.1038/sj.onc.1210939 DO - 10.1038/sj.onc.1210939 ID - Banerjee2008 ER - TY - JOUR AU - Hou, D. Y. AU - Muller, A. J. AU - Sharma, M. D. AU - DuHadaway, J. AU - Banerjee, T. AU - Johnson, M. PY - 2007 DA - 2007// TI - Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-2925 DO - 10.1158/0008-5472.CAN-06-2925 ID - Hou2007 ER - TY - JOUR AU - Muller, A. J. AU - DuHadaway, J. B. AU - Jaller, D. AU - Curtis, P. AU - Metz, R. AU - Prendergast, G. C. PY - 2010 DA - 2010// TI - Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-3613 DO - 10.1158/0008-5472.CAN-09-3613 ID - Muller2010 ER - TY - JOUR AU - Collins, L. K. AU - Chapman, M. S. AU - Carter, J. B. AU - Samie, F. H. PY - 2016 DA - 2016// TI - Cutaneous adverse effects of the immune checkpoint inhibitors JO - Curr Probl Cancer VL - 41 UR - https://doi.org/10.1016/j.currproblcancer.2016.12.001 DO - 10.1016/j.currproblcancer.2016.12.001 ID - Collins2016 ER - TY - JOUR AU - Soliman, H. H. AU - Minton, S. E. AU - Han, H. S. AU - Ismail-Khan, R. AU - Neuger, A. AU - Khambati, F. PY - 2016 DA - 2016// TI - A phase I study of indoximod in patients with advanced malignancies JO - Oncotarget VL - 7 ID - Soliman2016 ER - TY - JOUR AU - Gibney, G. AU - Hamid, O. AU - Lutsky, J. AU - Oszanski, A. AU - Gangadhar, T. AU - Gajewski, T. PY - 2015 DA - 2015// TI - Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma JO - Eur J Cancer VL - 51 UR - https://doi.org/10.1016/S0959-8049(16)30312-4 DO - 10.1016/S0959-8049(16)30312-4 ID - Gibney2015 ER - TY - JOUR AU - Zakharia, Y. AU - McWilliams, R. AU - Shaheen, M. AU - Shaheen, M. AU - Groissman, K. AU - Dranick, J. PY - 2017 DA - 2017// TI - Interim analysis of the phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma JO - Cancer Res VL - 13 ID - Zakharia2017 ER - TY - STD TI - Hamid O, Gajewski TF, Frankel AE, Bauer TM, Olszanski AJ, Luke JJ, et al. Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/ KEYNOTE-037 Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017, mdx377.001. ID - ref34 ER - TY - JOUR AU - Jha, G. G. AU - Gupta, S. AU - Tagawa, S. T. AU - Koopmeiners, J. S. AU - Vivek, S. AU - Dudek, A. Z. PY - 2017 DA - 2017// TI - A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.3066 DO - 10.1200/JCO.2017.35.15_suppl.3066 ID - Jha2017 ER - TY - JOUR AU - Burris, H. A. AU - Gordon, M. S. AU - Hellmann, M. D. AU - LoRusso, P. AU - Emens, L. A. AU - Hodi, S. PY - 2017 DA - 2017// TI - A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients with locally advanced or metastatic solid tumors JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.105 DO - 10.1200/JCO.2017.35.15_suppl.105 ID - Burris2017 ER -